Lilly's 'Triple-G' Obesity Drug Shows Strong Results in Alleviating Fatty Liver Disease.
TL;DR Summary
Eli Lilly's experimental obesity drug, retatrutide, significantly reduced liver fat in a small clinical trial of 98 patients with nonalcoholic fatty liver disease. Patients on the highest dose experienced an 86% decrease in liver fat over 48 weeks, with 93% achieving resolution of the disease. The results support further studies of the treatment against the increasingly common condition that lacks approved treatments.
Topics:business#clinical-trial#eli-lilly#health#liver-fat#nonalcoholic-fatty-liver-disease#obesity-drug
- Fatty liver disease was alleviated by Lilly's 'triple-G' obesity drug STAT
- A new weight-loss drug dubbed the 'triple G' could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery Yahoo Life
- Eli Lilly (LLY) Weight-Loss Shot Gives Company's Strongest Results in Trial Bloomberg
- Triple Agonist Retatrutide Hits New Weight-Loss Highs Medscape
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 1 min read
Condensed
63%
168 → 62 words
Want the full story? Read the original article
Read on STAT